Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCL9 | O00512 | 8/20 | 0.44 |
| ▸ | CTNNB1 | P35222 | 8/20 | 0.44 |
| ▸ | PAK4 | O96013 | 2/20 | 0.43 |
| ▸ | NAMPT | P43490 | 1/20 | 0.43 |
| ▸ | PAK1 | Q13153 | 1/20 | 0.43 |
| ▸ | FASN | P49327 | 2/20 | 0.41 |
| ▸ | CNR1 | P21554 | 1/20 | 0.39 |
| ▸ | HTR1A | P08908 | 4/20 | 0.39 |
| ▸ | ABL1 | P00519 | 1/20 | 0.38 |
| ▸ | BCR | P11274 | 1/20 | 0.38 |
| ▸ | MGLL | Q99685 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19066899 | 0.91 | BCL9 (0.52) | BCL9CTNNB1PAK4NAMPTPAK1 | |
| SCHEMBL18529797 | 0.88 | PAK4 (0.42) | PAK4NAMPTPAK1FASNHTR1A | |
| SCHEMBL18529800 | 0.84 | PAK4 (0.40) | PAK4NAMPTPAK1HTR1A | |
| SCHEMBL19082515 | 0.79 | PAK4 (0.47) | BCL9CTNNB1PAK4NAMPTPAK1 | |
| SCHEMBL18529735 | 0.79 | PAK4 (0.46) | PAK4NAMPTPAK1HTR1A | |
| SCHEMBL19066902 | 0.79 | PAK4 (0.48) | BCL9CTNNB1PAK4NAMPTPAK1 | |
| SCHEMBL16379649 | 0.78 | PAK4 (0.55) | PAK4NAMPTPAK1FASNCNR1 | |
| SCHEMBL29611757 | 0.75 | PAK4 (0.49) | PAK4NAMPTPAK1FASNCNR1 | |
| SCHEMBL18325907 | 0.75 | PAK4 (0.53) | PAK4NAMPTPAK1FASNCNR1 | |
| SCHEMBL19066856 | 0.74 | PAK4 (0.45) | BCL9CTNNB1PAK4NAMPTPAK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180244660-A1 | CYCLOPROPYLDERIVATIVES AND THEIR USE AS KINASE INHIBITORS | Karyopharm Therapeutics Inc. | 2018-08-30 | — | — | US | disclosed |
| WO-2017031204-A1 | CYCLOPROPYLDERIVATIVES AND THEIR USE AS KINASE INHIBITORS | Karyopharm Therapeutics Inc. (US) | 2017-02-23 | — | — | WO | disclosed |
| WO-2017031204-A1 | CYCLOPROPYLDERIVATIVES AND THEIR USE AS KINASE INHIBITORS | Karyopharm Therapeutics Inc. (US) | 2017-02-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180244660-A1 | CYCLOPROPYLDERIVATIVES AND THEIR USE AS KINASE INHIBITORS | MALT1, BCL9, IKBKE | BCL9 2/4885CTNNB1 1354/4885PAK4 265/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.